Regular Kratom Use Linked to Lower LDL and Favorable Lipid Profiles

Why it matters

A new human study from Indonesia found that regular kratom users had lower LDL cholesterol and better kidney function markers than non-users, with mitragynine levels negatively correlating with LDL — suggesting possible metabolic benefits worth investigating.

The big picture

The finding that kratom users show lower LDL and favorable renal markers challenges the simplistic harm-only narrative. It suggests kratom may have complex metabolic interactions that need longitudinal study to understand before any sweeping regulatory conclusions are drawn.

Key findings

• • 90 male participants from Putussibau District, West Kalimantan were studied: 64 kratom users vs. 26 non-users
• • Kratom users had significantly lower LDL, BUN, urea, and creatinine, with higher eGFR (better kidney filtration) than non-users
• • Serum mitragynine was negatively correlated with LDL and triglycerides — higher kratom alkaloid exposure associated with better lipid profiles
• • No significant differences in liver enzymes, HDL, glucose, or triglycerides between groups
• • Higher daily intake (>21 leaves/day) produced mild subclinical elevations in liver and renal markers
• • Systemic inflammation markers (hsCRP, IL-6) were linked to self-reported anxiety in users

Bottom line

Cross-sectional observational study; 90 male participants; Indonesia National Research and Innovation Agency; published in Medicine in Drug Discovery (2026).